KURE logo

KraneShares MSCI All China Health Care Index ETF (KURE) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

KURE representa a KraneShares MSCI All China Health Care Index ETF, una empresa del sector Financial Services con un precio de $ (capitalización de mercado 0). Calificado con 44/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 44/100

KraneShares MSCI All China Health Care Index ETF (KURE) Perfil de Servicios Financieros

Año de la oferta pública inicial (OPI)2018

KraneShares MSCI All China Health Care Index ETF (KURE) provides targeted exposure to the Chinese healthcare sector, tracking an index of free float adjusted market capitalization weighted companies. With a beta of 0.59 and assets under management of $0.08 billion, KURE offers investors a focused investment vehicle within the Chinese equity market.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

KURE presents a focused investment opportunity in the Chinese healthcare sector, driven by the increasing demand for healthcare services in China. The fund's strategy of mirroring the MSCI All China Health Care Index provides targeted exposure to this growth. Key value drivers include the expansion of China's healthcare infrastructure and increasing healthcare spending. Potential catalysts include regulatory reforms favoring the healthcare sector and advancements in medical technology within China. However, investors may want to evaluate risks such as regulatory changes, geopolitical tensions, and market volatility affecting Chinese equities. With a beta of 0.59, KURE exhibits lower volatility compared to the broader market.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • The fund invests at least 80% of its net assets in instruments in its underlying index.
  • The underlying index is a free float adjusted market capitalization weighted index.
  • The fund is designed to measure the equity market performance of Chinese companies in the healthcare sector.
  • The fund is non-diversified.
  • The fund has a beta of 0.59, indicating lower volatility compared to the market.

Competidores y Pares

Fortalezas

  • Targeted exposure to the Chinese healthcare sector.
  • Replication of a well-known index (MSCI All China Health Care Index).
  • Established brand recognition as a KraneShares ETF.
  • Relatively low beta of 0.59.

Debilidades

  • Non-diversified nature increases risk.
  • Concentration in a single country (China) exposes it to geopolitical risks.
  • Dependence on the performance of the Chinese healthcare sector.
  • Small market cap of $0.08B may limit liquidity.

Catalizadores

  • Ongoing: Expansion of China's healthcare infrastructure.
  • Ongoing: Increasing demand for specialized healthcare services.
  • Ongoing: Technological advancements in healthcare.
  • Ongoing: Regulatory support for healthcare innovation in China.

Riesgos

  • Potential: Regulatory changes in China affecting the healthcare sector.
  • Potential: Geopolitical tensions between China and other countries.
  • Potential: Economic slowdown in China.
  • Ongoing: Competition from other ETFs and investment funds.

Oportunidades de crecimiento

  • Increased Healthcare Spending in China: China's healthcare expenditure is projected to grow significantly, driven by an aging population and increasing urbanization. This growth translates to greater demand for healthcare services and products, benefiting companies within the KURE index. The Chinese government's focus on improving healthcare access and quality further supports this trend. This represents a long-term growth opportunity for KURE, aligning with the overall expansion of the Chinese healthcare market.
  • Technological Advancements in Healthcare: The integration of technology into healthcare, such as telemedicine, AI-driven diagnostics, and digital health platforms, is transforming the industry. Chinese healthcare companies are increasingly adopting these technologies to improve efficiency and patient outcomes. KURE's exposure to these innovative companies positions it to benefit from the technological advancements reshaping the healthcare landscape. This ongoing trend offers a sustained growth opportunity for the fund.
  • Regulatory Support for Healthcare Innovation: The Chinese government is actively promoting innovation in the healthcare sector through supportive policies and funding initiatives. These measures aim to foster the development of new drugs, medical devices, and healthcare services. KURE's holdings in companies engaged in research and development activities stand to gain from this regulatory support. This ongoing government backing creates a favorable environment for growth within the Chinese healthcare sector.
  • Expansion of Healthcare Infrastructure: China is investing heavily in expanding its healthcare infrastructure, including hospitals, clinics, and research facilities. This expansion creates opportunities for healthcare companies to provide equipment, supplies, and services to these new facilities. KURE's exposure to companies involved in the development and operation of healthcare infrastructure positions it to capitalize on this growth. This long-term infrastructure development supports sustained growth for the fund.
  • Increasing Demand for Specialized Healthcare Services: As China's middle class grows, there is increasing demand for specialized healthcare services, such as cancer treatment, cardiovascular care, and geriatric care. Chinese healthcare companies are expanding their offerings in these areas to meet this growing demand. KURE's exposure to companies providing specialized healthcare services allows it to benefit from this trend. This ongoing shift towards specialized care creates a valuable growth opportunity for the fund.

Oportunidades

  • Growth in the Chinese healthcare market due to aging population.
  • Increasing demand for specialized healthcare services.
  • Technological advancements in healthcare.
  • Regulatory support for healthcare innovation in China.

Amenazas

  • Regulatory changes in China affecting the healthcare sector.
  • Geopolitical tensions between China and other countries.
  • Economic slowdown in China.
  • Competition from other ETFs and investment funds.

Ventajas competitivas

  • Specialized focus on the Chinese healthcare sector.
  • Replication of the MSCI All China Health Care Index.
  • Established track record in the Chinese equity market.
  • Brand recognition as a KraneShares ETF.

Acerca de KURE

KraneShares MSCI All China Health Care Index ETF (KURE) is designed to provide investors with exposure to the healthcare sector within the Chinese equity market. The fund operates by investing at least 80% of its net assets, plus borrowings for investment purposes, in instruments that mirror its underlying index or possess similar economic characteristics. This underlying index is meticulously constructed as a free float adjusted market capitalization weighted index, adhering to the 10/40 Constraint, which is a diversification rule limiting the weight of any single component. KURE's primary objective is to closely track the equity market performance of Chinese companies operating in the healthcare sector, offering a focused investment tool for those seeking to capitalize on the growth and potential of China's healthcare industry. The fund is non-diversified, meaning it invests a larger percentage of its assets in a smaller number of issuers compared to a diversified fund.

Qué hacen

  • Invests in a portfolio of Chinese healthcare companies.
  • Tracks the MSCI All China Health Care Index.
  • Provides exposure to the Chinese healthcare sector.
  • Offers a focused investment vehicle for Chinese equities.
  • Replicates the performance of the underlying index.
  • Operates as a non-diversified fund.

Modelo de Negocio

  • Generates revenue through management fees.
  • Invests in Chinese healthcare companies.
  • Tracks the MSCI All China Health Care Index.
  • Provides a vehicle for investors to access the Chinese healthcare market.

Contexto de la Industria

KURE operates within the asset management industry, specifically focusing on providing access to the Chinese healthcare sector. The global asset management industry is experiencing growth, driven by increasing demand for specialized investment products. The Chinese healthcare market is expanding due to factors such as an aging population and rising income levels. KURE competes with other ETFs and investment funds offering exposure to Chinese equities and the healthcare sector. Competitors include funds with broader mandates or different weighting methodologies.

Clientes Clave

  • Institutional investors seeking exposure to Chinese healthcare.
  • Retail investors interested in the Chinese equity market.
  • Financial advisors looking for specialized investment products.
  • Pension funds and endowments seeking diversification.
Confianza de la IA: 71% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de KraneShares MSCI All China Health Care Index ETF (KURE): Price data unavailable

Últimas noticias

No hay noticias recientes disponibles para KURE.

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para KURE.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para KURE.

MoonshotScore

44/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de KURE en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Lo Que los Inversores Preguntan Sobre KraneShares MSCI All China Health Care Index ETF (KURE)

¿Cuáles son los factores clave para evaluar KURE?

KraneShares MSCI All China Health Care Index ETF (KURE) actualmente tiene una puntuación IA de 44/100, indicando puntuación baja. Fortaleza clave: Targeted exposure to the Chinese healthcare sector.. Riesgo principal a monitorear: Potential: Regulatory changes in China affecting the healthcare sector.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de KURE?

KURE actualmente puntúa 44/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de KURE?

Los precios de KURE se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre KURE?

La cobertura de analistas para KURE incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en KURE?

Las categorías de riesgo para KURE incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Regulatory changes in China affecting the healthcare sector.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de KURE?

La relación P/E para KURE compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está KURE sobrevalorada o infravalorada?

Determinar si KraneShares MSCI All China Health Care Index ETF (KURE) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de KURE?

KraneShares MSCI All China Health Care Index ETF (KURE) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • The information provided is based on available data and may be subject to change.
  • AI analysis is pending for KURE.
Fuentes de datos

Popular Stocks